NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

PharmaCyte Biotech, Inc. (PMCB) Stock Analysis

PharmaCyte Biotech, Inc. (PMCB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PMCB

$0.49

−$0.00 (−0.98%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PMCB with… →

PMCB Key Statistics

As of Sep 4, 2026
Trading
Open
$0.50
Previous Close
$0.49
Day's Range
0.49–0.50
52-Week Range
0.47–1.51
Volume
45.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.66
Valuation
Market Cap
$5.22M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.77
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
$30.66M+9084.98%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.74M
1-Year Return
−47.90%
Dividend and dates
Avg Volume
108.92K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PMCB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−32.80%
2025−53.89%
2024−27.31%
2023−26.28%
2022+17.20%
2021−75.93%
2020−83.46%
2019+9.46%
2018−33.69%
2017−62.53%
2016 (partial year)+242.30%

As of September 4, 2026.

PMCB Revenue and Earnings by Fiscal Year

FY ends April
Fiscal yearRevenueNet incomeNet margin
2024$0.00$30.66M—
2023$0.00$333.76K—
2022$0.00−$4.32M—
2021$0.00−$4.24M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2024$0.00—−$4.38M$30.66M—
2023$0.00—−$6.52M$333.76K—
2022$0.00—−$6.46M−$4.32M—
2021$0.00—−$4.39M−$4.24M—

Annual figures as reported, in the company's reporting currency. As of April 30, 2025.

PMCB Valuation vs Biotechnology Median

Median of 656 stocks
MetricPMCBBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

PharmaCyte Biotech, Inc. (PMCB) carries a market capitalisation of $5.22M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 2.

Over the past 52 weeks the price has ranged from $0.47 to $1.51. PMCB last closed at $0.49 on September 4, 2026. That is $0.00 (−0.98%) against the previous close. The latest close sits 3.47% above that 52-week low.

Financial Health

In fiscal 2024, PharmaCyte Biotech, Inc. reported revenue of $0.00. Net income for the same year was $30.66M. That is +9,084.98% against the prior fiscal year. Profit margin runs at 0%. Trailing earnings per share are −2.77.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2021 to $0.00 in 2024. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.66. Annualized volatility over the trailing 10 years is 120.11%. The trailing one-year price return is −47.90%. Across 10 years the annualized return works out at −38.40%.

Growth & Income

No dividend is on file for PMCB.

Across the complete calendar years on file, 2022 returned +17.20% and 2020 returned −83.46%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is −32.80%.

Peer Comparison

PharmaCyte Biotech, Inc. (PMCB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PharmaCyte Biotech, Inc. PMCB $5.22M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. PharmaCyte Biotech, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Visit website →